Acquisition of Functional Antibodies That Block the Binding of Erythrocyte-Binding Antigen 175 and Protection Against Plasmodium falciparum Malaria in Children

Clinical Infectious Diseases

Volumn 61, Issue 8, 2015, Pages 1244-1252

  Irani, Vashti ^a,b,c   Ramsland, Paul A ^a,b,c,d   Guy, Andrew J ^a,c   Siba, Peter M ^e   Mueller, Ivo ^f,g   Richards, Jack S ^a,b,c   Beeson, James G ^a,b,c  

^a BURNET INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d CURTIN UNIVERSITY   (Australia)

^e PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^f WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^g CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

Author keywords

Antibodies; Binding inhibition; EBA 175; Malaria; Plasmodium falciparum

Indexed keywords

ARTESUNATE; ERYTHROCYTE ANTIGEN; ERYTHROCYTE BINDING ANTIGEN 175; GLYCOPHORIN A; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; ERYTHROCYTE-BINDING ANTIGEN 175, PLASMODIUM; GLYCOPHORIN; PARASITE ANTIGEN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ADOLESCENT; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME INHIBITION ASSAY; ERYTHROCYTE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; PARASITEMIA; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RECEPTOR BINDING; BINDING SITE; BLOOD; FEMALE; IMMUNOASSAY; IMMUNOLOGY; MALARIA, FALCIPARUM; MALE; MEROZOITE; METABOLISM; PARASITOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BINDING SITES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; GLYCOPHORIN; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; MALARIA, FALCIPARUM; MALE; MEROZOITES; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS;

EID: 84943268540     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ525     Document Type: Article

References (39)

1. WHO. Global Malaria Programme: World Malaria Report 2013. November 2013 ed. Geneva: World Health Organisation, 2013.
2. Richards JS, Beeson JG. The future for blood-stage vaccines against malaria. Immunol Cell Biol 2009; 87:377-90.
3. Marsh K, Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol 2006; 28:51-60.
4. Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. Clin Microbiol Rev 2009; 22:13-36.
5. Beeson JG, Fowkes FJI, Reiling L, Osier FH, Drew DR, Brown GV. Correlates of protection for Plasmodium falciparum malaria vaccine development: current knowledge and future research. In: Corradin G., Engers H., eds. Malaria vaccine development: over 40 years of trials and tribulations. UK: Future Medicine Ltd, 2014:80-104.
6. Osier FH, Feng G, Boyle MJ, et al. Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria. BMC Med 2014; 12:108.
7. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 1995; 182:409-18.
8. Boyle Michelle J, Reiling L, Feng G, et al. Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria. Immunity 2015; 42:580-90.
9. Duncan CJ, Hill AV, Ellis RD. Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? Hum Vaccin Immunother 2012; 8:706-14.
10. Sim BK, Chitnis CE, Wasniowska K, Hadley TJ, Miller LH. Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum. Science 1994; 264:1941-4.
11. Tham W-H, Healer J, Cowman AF. Erythrocyte and reticulocyte binding-like proteins of Plasmodium falciparum. Trends Parasitol 2012; 28:23-30.
12. Richards JS, Stanisic DI, Fowkes FJ, et al. Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin Infect Dis 2010; 51:e50-60.
13. McCarra MB, Ayodo G, Sumba PO, et al. Antibodies to Plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria. Pediatr Infect Dis J 2011; 30:1037-42.
14. Persson KE, Fowkes FJ, McCallum FJ, et al. Erythrocyte-binding antigens of Plasmodium falciparum are targets of human inhibitory antibodies and function to evade naturally acquired immunity. J Immunol 2013; 191:785-94.
15. Badiane AS, Bei AK, Ahouidi AD, et al. Inhibitory humoral responses to the Plasmodium falciparum vaccine candidate EBA-175 are independent of erythrocyte invasion pathway. Clin Vaccine Immunol 2013; 20:1238-45.
16. Ohas EA, Adams JH,Waitumbi JN, et al. Measurement of antibody levels against region II of the erythrocyte-binding antigen 175 of Plasmodium falciparum in an area of malaria holoendemicity in western Kenya. Infect Immun 2004; 72:735-41.
17. El Sahly HM, Patel SM, Atmar RL, et al. Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 region II malaria vaccine in healthy adults living in an area where malaria is not endemic. Clin Vaccine Immunol 2010; 17:1552-9.
18. Adams JH, Blair PL, Kaneko O, Peterson DS. An expanding ebl family of Plasmodium falciparum. Trends Parasitol 2001; 17:297-9.
19. Adams JH, Sim BK, Dolan SA, Fang X, Kaslow DC, Miller LH. A family of erythrocyte binding proteins of malaria parasites. Proc Natl Acad Sci U S A 1992; 89:7085-9.
20. Sim BK, Toyoshima T, Haynes JD, Aikawa M. Localization of the 175-kilodalton erythrocyte binding antigen in micronemes of Plasmodium falciparum merozoites. Mol Biochem Parasitol 1992; 51:157-9.
21. Aikawa M, Miller LH, Johnson J, Rabbege J. Erythrocyte entry by malarial parasites. A moving junction between erythrocyte and parasite. J Cell Biol 1978; 77:72-82.
22. O'Donnell RA, Hackett F, Howell SA, et al. Intramembrane proteolysis mediates shedding of a key adhesin during erythrocyte invasion by the malaria parasite. J Cell Biol 2006; 174:1023-33.
23. Healer J, Thompson JK, Riglar DT, et al. Vaccination with conserved regions of erythrocyte-binding antigens induces neutralizing antibodies against multiple strains of Plasmodium falciparum. PLoS One 2013; 8: e72504.
24. Michon P, Cole-Tobian JL, Dabod E, et al. The risk of malarial infections and disease in Papua New Guinean children. Am J Trop Med Hyg 2007; 76:997-1008.
25. Richards JS, Arumugam TU, Reiling L, et al. Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol 2013; 191:795-809.
26. Stanisic DI, Richards JS, McCallum FJ, et al. Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun 2009; 77:1165-74.
27. NarumDL, Haynes JD, Fuhrmann S, et al. Antibodies against the Plasmodium falciparum receptor binding domain of EBA-175 block invasion pathways that do not involve sialic acids. Infect Immun 2000; 68:1964-6.
28. Camus D, Hadley TJ. A Plasmodium falciparum antigen that binds to host erythrocytes and merozoites. Science 1985; 230:553-6.
29. ICH Harmonised Tripartite Guideline. Validation of Analytical Procedures: Text and Methodology Q2(R1). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), 2005.
30. Ondigo BN, Hodges JS, Ireland KF, et al. Estimation of recent and longterm malaria transmission in a population by antibody testing to multiple Plasmodium falciparum antigens. J Infect Dis 2014; 210:1123-32.
31. Polley SD, Mwangi T, Kocken CH, et al. Human antibodies to recombinant protein constructs of Plasmodium falciparum apical membrane antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 2004; 23:718-28.
32. Liang H, Narum DL, Fuhrmann SR, Luu T, Sim BK. A recombinant baculovirus-expressed Plasmodium falciparum receptor-binding domain of erythrocyte binding protein EBA-175 biologically mimics native protein. Infect Immun 2000; 68:3564-8.
33. Jiang L, Gaur D, Mu J, Zhou H, Long CA, Miller LH. Evidence for erythrocyte-binding antigen 175 as a component of a ligand-blocking blood-stage malaria vaccine. Proc Natl Acad Sci U S A 2011; 108: 7553-8.
34. Wanaguru M, Liu W, Hahn BH, Rayner JC, Wright GJ. RH5-basigin interaction plays a major role in the host tropism of Plasmodium falciparum. Proc Natl Acad Sci U S A 2013; 110:20735-40.
35. Salinas ND, Paing MM, Tolia NH. Critical glycosylated residues in exon three of erythrocyte glycophorin a engage Plasmodium falciparum EBA-175 and define receptor specificity. MBio 2014; 5:e01606-14.
36. Tolia NH, Enemark EJ, Sim BK, Joshua-Tor L. Structural basis for the EBA-175 erythrocyte invasion pathway of the malaria parasite Plasmodium falciparum. Cell 2005; 122:183-93.
37. Chen E, Paing MM, Salinas N, Sim BK, Tolia NH. Structural and functional basis for inhibition of erythrocyte invasion by antibodies that target Plasmodium falciparum EBA-175. PLoS Pathog 2013; 9: e1003390.
38. Mwangi TW, Ross A, Snow RW, Marsh K. Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. J Infect Dis 2005; 191:1932-9.
39. Bejon P, Berkley JA, Mwangi T, et al. Defining childhood severe falciparum malaria for intervention studies. PLoS Med 2007; 4:e251.